The Latin America, Middle East and Africa Hemoglobinopathies Market would witness market growth of 8.6% CAGR during the forecast period (2022-2028).
To measure the level of different types of hemoglobin in the blood, hemoglobin electrophoresis is used. Hb electrophoresis, sickle cell – electrophoresis, and hemoglobinopathy – electrophoresis are some of the alternative names used for this test. A notable level of HbA and HbA2 is present in healthy adults, but some individuals may also have a small amount of HbF in their blood. This is the primary type of hemoglobin in the body of an unborn child.
Some illnesses are also connected with the amount of HbF in the blood (only if the level of HbF is more than 2% of the total hemoglobin). The abnormal form of hemoglobin associated with sickle cell anemia is HbS, and the other unusual hemoglobin form HbC is associated with hemolytic anemia. Its symptoms are quite mild when compared to sickle cell anemia. Hemoglobinopathies are genetic disorders. They are taken on as single-gene illnesses, causing problems like sickle cell disease.
Genetic and blood testing, hemoglobin electrophoresis, HbA2 quantitative analysis by ion exchange column chromatography, pre-implantation genetic diagnosis, and alkaline & acid gel electrophoresis are the most widely used tests for the identification of thalassemia and other hemoglobinopathy diseases. Hemoglobinopathies are considered to be one of the most widely diagnosed inherited diseases. Also, due to immigration, it has become common in other parts of the world.
In Middle Eastern Arab countries, the Sickle hemoglobin (HbS) gene occurs at a different frequency, with unique distribution patterns and a picture of overall blood genetic disorders in the region. The origin of the gene is disputed, but studies have shown, using beta-globin gene haplotypes, that there were various origins for Sickle hemoglobin. The sickle hemoglobin gene is common and displays polymorphism in some regions, while the vice versa is also true in other regions.
The Brazil market dominated the LAMEA Hemoglobinopathies Market by Country in 2021; thereby, achieving a market value of $105.4 Million by 2028. The Argentina market is showcasing a CAGR of 9.2% during (2022 - 2028). Additionally, The UAE market would register a CAGR of 8.3% during (2022 - 2028).
Based on Type, the market is segmented into Thalassemia, Sickle Cell Disease and Others. Based on Distribution Channel, the market is segmented into Drug Stores & Retail Pharmacy, Hospital Pharmacy and Online Providers. Based on Therapy, the market is segmented into Monoclonal Antibody Medication, Hydroxyurea, ACE Inhibitors and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
Free Valuable Insights: The Global Hemoglobinopathies Market is Predict to reach $6 Billion by 2028, at a CAGR of 5.6%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Sanofi S.A., Danaher Corporation, Pfizer, Inc. (Global Blood Therapeutics, Inc.), Merck & Co., Inc., Bristol Myers Squibb Company, Alnylam Pharmaceuticals, Inc., Emmaus Life Sciences, Inc., Biogen, Inc. and Canthera Discovery Ltd.
Scope of the Study
Market Segments Covered in the Report:
By Type
- Thalassemia
- Sickle Cell Disease
- Others
By Distribution Channel
- Drug Stores & Retail Pharmacy
- Hospital Pharmacy
- Online Providers
By Therapy
- Monoclonal Antibody Medication
- Hydroxyurea
- ACE Inhibitors
- Others
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Abbott Laboratories
- Sanofi S.A.
- Danaher Corporation
- Pfizer, Inc. (Global Blood Therapeutics, Inc.)
- Merck & Co., Inc.
- Bristol Myers Squibb Company
- Alnylam Pharmaceuticals, Inc.
- Emmaus Life Sciences, Inc.
- Biogen, Inc.
- Canthera Discovery Ltd.
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Hemoglobinopathies Market, by Type
1.4.2 LAMEA Hemoglobinopathies Market, by Distribution Channel
1.4.3 LAMEA Hemoglobinopathies Market, by Therapy
1.4.4 LAMEA Hemoglobinopathies Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market composition and Scenarios
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. LAMEA Hemoglobinopathies Market by Type
3.1 LAMEA Thalassemia Market by Country
3.2 LAMEA Sickle Cell Disease Market by Country
3.3 LAMEA Others Market by Country
Chapter 4. LAMEA Hemoglobinopathies Market by Distribution Channel
4.1 LAMEA Drug Stores & Retail Pharmacy Market by Country
4.2 LAMEA Hospital Pharmacy Market by Country
4.3 LAMEA Online Providers Market by Country
Chapter 5. LAMEA Hemoglobinopathies Market by Therapy
5.1 LAMEA Monoclonal Antibody Medication Market by Country
5.2 LAMEA Hydroxyurea Market by Country
5.3 LAMEA ACE Inhibitors Market by Country
5.4 LAMEA Others Market by Country
Chapter 6. LAMEA Hemoglobinopathies Market by Country
6.1 Brazil Hemoglobinopathies Market
6.1.1 Brazil Hemoglobinopathies Market by Type
6.1.2 Brazil Hemoglobinopathies Market by Distribution Channel
6.1.3 Brazil Hemoglobinopathies Market by Therapy
6.2 Argentina Hemoglobinopathies Market
6.2.1 Argentina Hemoglobinopathies Market by Type
6.2.2 Argentina Hemoglobinopathies Market by Distribution Channel
6.2.3 Argentina Hemoglobinopathies Market by Therapy
6.3 UAE Hemoglobinopathies Market
6.3.1 UAE Hemoglobinopathies Market by Type
6.3.2 UAE Hemoglobinopathies Market by Distribution Channel
6.3.3 UAE Hemoglobinopathies Market by Therapy
6.4 Saudi Arabia Hemoglobinopathies Market
6.4.1 Saudi Arabia Hemoglobinopathies Market by Type
6.4.2 Saudi Arabia Hemoglobinopathies Market by Distribution Channel
6.4.3 Saudi Arabia Hemoglobinopathies Market by Therapy
6.5 South Africa Hemoglobinopathies Market
6.5.1 South Africa Hemoglobinopathies Market by Type
6.5.2 South Africa Hemoglobinopathies Market by Distribution Channel
6.5.3 South Africa Hemoglobinopathies Market by Therapy
6.6 Nigeria Hemoglobinopathies Market
6.6.1 Nigeria Hemoglobinopathies Market by Type
6.6.2 Nigeria Hemoglobinopathies Market by Distribution Channel
6.6.3 Nigeria Hemoglobinopathies Market by Therapy
6.7 Rest of LAMEA Hemoglobinopathies Market
6.7.1 Rest of LAMEA Hemoglobinopathies Market by Type
6.7.2 Rest of LAMEA Hemoglobinopathies Market by Distribution Channel
6.7.3 Rest of LAMEA Hemoglobinopathies Market by Therapy
Chapter 7. Company Profiles
7.1 Abbott Laboratories
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expense
7.1.5 SWOT Analysis
7.2 Sanofi S.A.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental and Regional Analysis
7.2.4 Research & Development Expense
7.2.5 Recent strategies and developments:
7.2.5.1 Trials and Approvals:
7.3 Danaher Corporation
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Segmental and Regional Analysis
7.3.4 Research & Development Expense
7.4 Pfizer, Inc. (Global Blood Therapeutics, Inc.)
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Regional & Segmental Analysis
7.4.4 Research & Development Expense
7.4.5 Recent strategies and developments:
7.4.5.1 Partnerships, Collaborations, and Agreements:
7.4.5.2 Approvals and Trials:
7.5 Merck & Co., Inc.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expenses
7.6 Bristol Myers Squibb Company
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Regional Analysis
7.6.4 Research & Development Expenses
7.7 Alnylam Pharmaceuticals, Inc.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Research & Development Expense
7.8 Emmaus Life Sciences, Inc.
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Research & Development Expenses
7.9 Biogen, Inc.
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Regional Analysis
7.9.4 Research & Development Expense
7.10. Canthera Discovery Ltd.
7.10.1 Company Overview
TABLE 1 LAMEA Hemoglobinopathies Market, 2018 - 2021, USD Million
TABLE 2 LAMEA Hemoglobinopathies Market, 2022 - 2028, USD Million
TABLE 3 LAMEA Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
TABLE 4 LAMEA Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
TABLE 5 LAMEA Thalassemia Market by Country, 2018 - 2021, USD Million
TABLE 6 LAMEA Thalassemia Market by Country, 2022 - 2028, USD Million
TABLE 7 LAMEA Sickle Cell Disease Market by Country, 2018 - 2021, USD Million
TABLE 8 LAMEA Sickle Cell Disease Market by Country, 2022 - 2028, USD Million
TABLE 9 LAMEA Others Market by Country, 2018 - 2021, USD Million
TABLE 10 LAMEA Others Market by Country, 2022 - 2028, USD Million
TABLE 11 LAMEA Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 12 LAMEA Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 13 LAMEA Drug Stores & Retail Pharmacy Market by Country, 2018 - 2021, USD Million
TABLE 14 LAMEA Drug Stores & Retail Pharmacy Market by Country, 2022 - 2028, USD Million
TABLE 15 LAMEA Hospital Pharmacy Market by Country, 2018 - 2021, USD Million
TABLE 16 LAMEA Hospital Pharmacy Market by Country, 2022 - 2028, USD Million
TABLE 17 LAMEA Online Providers Market by Country, 2018 - 2021, USD Million
TABLE 18 LAMEA Online Providers Market by Country, 2022 - 2028, USD Million
TABLE 19 LAMEA Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
TABLE 20 LAMEA Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
TABLE 21 LAMEA Monoclonal Antibody Medication Market by Country, 2018 - 2021, USD Million
TABLE 22 LAMEA Monoclonal Antibody Medication Market by Country, 2022 - 2028, USD Million
TABLE 23 LAMEA Hydroxyurea Market by Country, 2018 - 2021, USD Million
TABLE 24 LAMEA Hydroxyurea Market by Country, 2022 - 2028, USD Million
TABLE 25 LAMEA ACE Inhibitors Market by Country, 2018 - 2021, USD Million
TABLE 26 LAMEA ACE Inhibitors Market by Country, 2022 - 2028, USD Million
TABLE 27 LAMEA Others Market by Country, 2018 - 2021, USD Million
TABLE 28 LAMEA Others Market by Country, 2022 - 2028, USD Million
TABLE 29 LAMEA Hemoglobinopathies Market by Country, 2018 - 2021, USD Million
TABLE 30 LAMEA Hemoglobinopathies Market by Country, 2022 - 2028, USD Million
TABLE 31 Brazil Hemoglobinopathies Market, 2018 - 2021, USD Million
TABLE 32 Brazil Hemoglobinopathies Market, 2022 - 2028, USD Million
TABLE 33 Brazil Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
TABLE 34 Brazil Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
TABLE 35 Brazil Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 36 Brazil Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 37 Brazil Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
TABLE 38 Brazil Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
TABLE 39 Argentina Hemoglobinopathies Market, 2018 - 2021, USD Million
TABLE 40 Argentina Hemoglobinopathies Market, 2022 - 2028, USD Million
TABLE 41 Argentina Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
TABLE 42 Argentina Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
TABLE 43 Argentina Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 44 Argentina Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 45 Argentina Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
TABLE 46 Argentina Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
TABLE 47 UAE Hemoglobinopathies Market, 2018 - 2021, USD Million
TABLE 48 UAE Hemoglobinopathies Market, 2022 - 2028, USD Million
TABLE 49 UAE Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
TABLE 50 UAE Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
TABLE 51 UAE Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 52 UAE Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 53 UAE Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
TABLE 54 UAE Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
TABLE 55 Saudi Arabia Hemoglobinopathies Market, 2018 - 2021, USD Million
TABLE 56 Saudi Arabia Hemoglobinopathies Market, 2022 - 2028, USD Million
TABLE 57 Saudi Arabia Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
TABLE 58 Saudi Arabia Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
TABLE 59 Saudi Arabia Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 60 Saudi Arabia Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 61 Saudi Arabia Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
TABLE 62 Saudi Arabia Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
TABLE 63 South Africa Hemoglobinopathies Market, 2018 - 2021, USD Million
TABLE 64 South Africa Hemoglobinopathies Market, 2022 - 2028, USD Million
TABLE 65 South Africa Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
TABLE 66 South Africa Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
TABLE 67 South Africa Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 68 South Africa Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 69 South Africa Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
TABLE 70 South Africa Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
TABLE 71 Nigeria Hemoglobinopathies Market, 2018 - 2021, USD Million
TABLE 72 Nigeria Hemoglobinopathies Market, 2022 - 2028, USD Million
TABLE 73 Nigeria Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
TABLE 74 Nigeria Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
TABLE 75 Nigeria Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 76 Nigeria Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 77 Nigeria Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
TABLE 78 Nigeria Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
TABLE 79 Rest of LAMEA Hemoglobinopathies Market, 2018 - 2021, USD Million
TABLE 80 Rest of LAMEA Hemoglobinopathies Market, 2022 - 2028, USD Million
TABLE 81 Rest of LAMEA Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
TABLE 82 Rest of LAMEA Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
TABLE 83 Rest of LAMEA Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 84 Rest of LAMEA Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 85 Rest of LAMEA Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
TABLE 86 Rest of LAMEA Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
TABLE 87 Key Information – Abbott Laboratories
TABLE 88 Key Information – Sanofi S.A.
TABLE 89 Key Information – Danaher Corporation
TABLE 90 Key Information – Pfizer, Inc.
TABLE 91 KEY INFORMATION - Merck & Co., Inc.
TABLE 92 Key Information – Bristol Myers Squibb Company
TABLE 93 Key Information – Alnylam Pharmaceuticals, Inc.
TABLE 94 Key Information – Emmaus Life Sciences, INC.
TABLE 95 Key Information – Biogen, Inc.
TABLE 96 Key Information – Canthera Discovery Ltd.
List of Figures
FIG 1 Methodology for the research
FIG 2 Swot analysis: Abbott laboratories